Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Tapentadol is a novel oral analgesic with a dual mode of action as an agonist of the -opioid receptor (MOR), and as a norepinephrine reuptake inhibitor (NRI) all in a single molecule. Immediate release (IR) tapentadol shows its analgesic effect quickly, at around 30 minutes. Its MOR agonistic action produces acute nociceptive pain relief; its role as an NRI brings about chronic neuropathic pain relief. Absorption is rapid, with a mean maximal serum concentration at 1.25−1.5 h after oral intake. It is present primarily in the form of conjugated metabolites after glucuronidation, and excretes rapidly and completely via the kidneys. The most common adverse reactions are nausea, dizziness, vomiting, and somnolence. Constipation is more common in use of the ER formulation. Precautions against concomitant use of central nervous system depressants, including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, and alcohol, or use of tapentadol within 14 days of the cessation of monoamine oxidase inhibitors, are advised. The safety and efficacy have not been established for use during pregnancy, labor, and delivery, or for nursing mothers, pediatric patients less than 18 years of age, and cases of severe renal impairment and severe hepatic impairment. The major concerns for tapentadol are abuse, addiction, seeking behavior, withdrawal, and physical dependence. The presumed problem for use of tapentadol is to control the ratio of MOR agonist and NRI. In conclusion, tapentadol produces both nociceptive and neuropathic pain relief, but with worries about abuse and dependence. (Korean J Pain 2016; 29: 153-7)
Abstract
Tapentadol is a novel oral analgesic with a dual mode of action as an agonist of the -opioid receptor (MOR), and as a norepinephrine reuptake inhibitor (NRI) all in a single molecule. Immediate release (IR) tapentadol shows its analgesic effect quickly, at around 30 minutes. Its MOR agonistic action produces acute nociceptive pain relief; its role as an NRI brings about chronic neuropathic pain relief. Absorption is rapid, with a mean maximal serum concentration at 1.25−1.5 h after oral intake. It is present primarily in the form of conjugated metabolites after glucuronidation, and excretes rapidly and completely via the kidneys. The most common adverse reactions are nausea, dizziness, vomiting, and somnolence. Constipation is more common in use of the ER formulation. Precautions against concomitant use of central nervous system depressants, including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, and alcohol, or use of tapentadol within 14 days of the cessation of monoamine oxidase inhibitors, are advised. The safety and efficacy have not been established for use during pregnancy, labor, and delivery, or for nursing mothers, pediatric patients less than 18 years of age, and cases of severe renal impairment and severe hepatic impairment. The major concerns for tapentadol are abuse, addiction, seeking behavior, withdrawal, and physical dependence. The presumed problem for use of tapentadol is to control the ratio of MOR agonist and NRI. In conclusion, tapentadol produces both nociceptive and neuropathic pain relief, but with worries about abuse and dependence. (Korean J Pain 2016; 29: 153-7)
참고문헌 (24)
- Lassen D, "The pharmacogenetics of tramadol", Clin Pharmacokinet, 54, pp.825~836 (2015)
- Farquhar-Smith P, "Tramadol and acetaminophen combination for chronic non-cancer pain", Expert Opin Pharmacother, 14, pp.2297~2304 (2013)
- Kress HG, "Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?", Eur J Pain, 14, pp.781~783 (2010)
- Dart RC, "Nonmedical use of tapentadol immediate release by college students", Clin J Pain, 30, pp.685~692 (2014)
- Dart RC, "Assessment of the abuse of tapentadol immediate release : the first 24 months", J Opioid Manag, 8, pp.395~402 (2012)
- Buschmann H, "Analogue-based drug discovery III", pp.295~318 (2013), Wiley-VCH
- Wade WE, "Tapentadol hydrochloride : a centrally acting oral analgesic", Clin Ther, 31, pp.2804~2818 (2009)
- Smyth LA, "Measuring and interpreting the selectivity of protein kinase inhibitors", J Chem Biol, 2, pp.131~151 (2009)
- Tzschentke TM, "Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis", Neurosci Lett, 507, pp.151~155 (2012)
- Ramaswamy S, "Tapentadol--the evidence so far", Anaesthesia, 70, pp.518~522 (2015)
- 옥영민, "Nefopam Reduces Dysesthesia after Percutaneous Endoscopic Lumbar Discectomy", The Korean Journal of Pain, 29(1), pp.40~47 (2016), 대한통증학회
- 김경훈, "Rediscovery of Nefopam for the Treatment of Neuropathic Pain", The Korean Journal of Pain, 27(2), pp.103~111 (2014), 대한통증학회
- Barber J, "Examining the use of tramadol hydrochloride as an antidepressant", Exp Clin Psychopharmacol, 19, pp.123~130 (2011)
- Terlinden R, "Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects", Eur J Drug Metab Pharmacokinet, 32, pp.163~169 (2007)
- Singh DR, "Tapentadol hydrochloride : a novel analgesic", Saudi J Anaesth, 7, pp.322~326 (2013)
- 박찬홍, "Comparison of Morphine and Tramadol in Transforaminal Epidural Injections for Lumbar Radicular Pain", The Korean Journal of Pain, 26(3), pp.265~269 (2013), 대한통증학회
- Xu XS, "Population pharmacokinetics of tapentadol immediate release(IR)in healthy subjects and patients with moderate or severe pain", Clin Pharmacokinet, 49, pp.671~682 (2010)
- Afilalo M, "Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study", Clin Drug Investig, 30, pp.489~505 (2010)
- Cepeda MS, "Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone : results from a cohort study", J Pain, 14, pp.1227~1241 (2013)
- Cepeda MS, "Comparison of opioid doctor shopping for tapentadol and oxycodone : a cohort study", J Pain, 14, pp.158~164 (2013)
- Dart RC, "Diversion and illicit sale of extended release tapentadol in the United States", Pain Med (2015)
- Butler SF, "Tapentadol abuse potential : a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment", Pain Med, 16, pp.119~130 (2015)
- McNaughton EC, "Assessing abuse potential of new analgesic medications following market release : an evaluation of internet discussion of tapentadol abuse", Pain Med, 16, pp.131~140 (2015)
- Vosburg SK, "A comparison among tapentadol tamperresistant formulations(TRF)and OxyContinⓇ(non-TRF)in prescription opioid abusers", Addiction, 108, pp.1095~1106 (2013)